Meeting
2018 ASCO Annual Meeting
Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab.
Authors
Shiro Kimbara
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Shiro Kimbara , Yutaka Fujiwara , Shintaro Iwama , Ken Ohashi , Aya Kuchiba , Hiroshi Arima , Naoya Yamazaki , Shigehisa Kitano , Noboru Yamamoto , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9091)
DOI
10.1200/JCO.2018.36.15_suppl.9091
Abstract #
9091
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer.
First Author: Christopher Jakubowski
Poster
2019 ASCO Annual Meeting
The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.
First Author: Rohit K. Jain
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Cancer-immune checkpoint inhibition and autoimmune-related adverse events.
First Author: Joerg Rathmann
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.
First Author: Ann W. Silk